Satellos Bioscience Inc. MSCL.TO
9.50 CAD -0.07 (-0.73%)
As ofNov 13, 2026, 3:59 PM EST
9.28 Day range 10.24
7.56 52-week range 18.98
- YTD
- +19.95%
- 1 year
- +14.73%
- Market cap
- 201.56M
- EPS (ttm)
- -2.70
- Shares out
- 113.60M
- Forward P/E
- -4.05
- YTD return
- +19.95%
- 1-year return
- +14.73%
- Volume
- 6.49K
- Avg volume
- 11.96K
- Open
- 10.24
- Previous close
- 9.57
- Day's range
- 9.28 – 10.24
- 52-week range
- 7.56 – 18.98
- Beta
- 1.03
No chart data for this range yet.
Key statistics
- Enterprise value
- 65.97M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.98M
- Total cash
- 27.70M
- Total debt
- 0
- Return on equity
- -58.84%
- Short % of float
- 0.00%
- 50-day average
- 0.8074
- 200-day average
- 0.58125
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- satellos.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on MSCL.TO — it syncs with the Stock Master app.
